ArticleBMC public health2025
Trend of the lipid profile in a cohort with severe hypercholesterolemia in Osona county (Barcelona, Spain), between 2009 and 2021.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVarious studies confirm that the prevalence of dyslipidemia and other cardiovascular factors is high.
objectiveTo evaluate the trend of the lipid profile (LP) in a cohort with severe hypercholesterolemia and its relationship with lipid-lowering treatment during the period 2009-2021.
methodsCross-sectional study carried out in the Osona county (Barcelona). Outpatients from the first period (2009-2011) who were aged between 25 and 65 years and had severe hypercholesterolemia were selected (n = 2,608). In a second period (2019-2021), these patients (n = 1,855) were followed up to evaluate the trend of LP and its relationship with lipid-lowering treatment. The Student's T-test (paired data) was used to identify differences between observations from the two periods.
resultsLipid-lowering treatment was prescribed to 61.9% of patients. The group of patients of the cohort improved the data of the mean results of the LP. Approximately 75% of cases were unable to establish their cholesterol and atherogenic fraction values. The prescription of lipid-lowering treatment in the cardiovascular disease group (CVD) was 80.9% vs 61.9% of the total cohort.
conclusionThree out of four cases failed to reduce the levels of LDL-C and non-HDL-C, recommended by the guidelines of scientific societies. Primary Care is the ideal framework to implement improvement strategies to control severe hypercholesterolemia, and it is therefore essential to strengthen it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.